Abbott Laboratories Stock News

I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I discuss two scenarios of hypothetical ...

Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation of a truncated custom quality score could have generated a total return nearly double that of the S&P 500 during the last 9 years.

A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets.

Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.

My initial rating of Abbott Laboratories is a buy, agreeing with today's Wall Street consensus. The future growth indicators, diversified portfolio across many clinical segments, and leading roles in diabetic & cardiology care make this one a winner.

It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.

What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase.

As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger.